Bristol: Zeposia Analyses Show Benefits in Relapsing Multiple Sclerosis Treatment

 Bristol Myers Squibb said Friday new analyses from two Phase 3 trials of Zeposia showed early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis, a disease in which the immune system attacks the protective covering of nerves.

The biopharmaceutical product developer said the greatest effect from the demonstrated cognitive benefits were seen in people with high thalamic volume, supporting an association between preserved brain volume and improved long-term cognitive outcomes.

Zeposia was well tolerated with more than 80% of people who started the Phase 3 SUNBEAM trial remaining on continuous therapy through 48 months of the Phase 3 DAYBREAK OLE study, Bristol Myers Squibb said.

https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Says-Zeposia-Analyses-Show-Benefits-in-Relapsing-Multiple-Sclerosis-Treatment-40810021/